Fate Therapeutics shareholders approve 7M share increase to stock plan at annual meeting

FATE THERAPEUTICS INC

Stockholders approved 3rd A&R 2022 Stock Plan adding 7M shares; votes: 46.6M for, 14.3M against (26.1M broker non-votes).
Directors Epstein, Jooss, Hamill re-elected with 59.3M, 59.7M, 60.9M votes for, respectively.
Ernst & Young ratified as independent auditor for FY2026; 86.6M for, 0.3M against.
Non-binding advisory vote on executive compensation passed with 59.2M for, 1.8M against.

item 5.02 item 5.07 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

FATE THERAPEUTICS INC shareholders approved Election of Class I Directors at the 2026-06-12 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-12

Exact text from the filing

(i) Election of Class I Directors. Director Nominee For Withheld Broker Non-Votes Robert S. Epstein, M.D., M.S. 59,332,820 1,717,842 26,083,760 Karin Jooss, Ph.D. 59,655,584 1,395,078 26,083,760 Laura J. Hamill 60,850,004 200,658 26,083,760

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

FATE THERAPEUTICS INC shareholders approved Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-12 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-12

Exact text from the filing

(ii) Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. For Against Abstain Broker Non-Votes 86,552,927 308,582 272,913 0

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

FATE THERAPEUTICS INC shareholders approved Non-binding advisory vote on the compensation of the Company’s named executive officers at the 2026-06-12 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2026-06-12

Exact text from the filing

(iii) Non-binding advisory vote on the compensation of the Company’s named executive officers. For Against Abstain Broker Non-Votes 59,168,689 1,808,669 73,304 26,083,760

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

FATE THERAPEUTICS INC shareholders approved Approval of an amendment to the Amended and Restated 2022 Stock Option and Incentive Plan to increase the number of shares of Common Stock reserved for issuance by 7,000,000 shares at the 2026-06-12 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2026-06-12

Exact text from the filing

(iv) Approval of an amendment and restatement of the 2022 A&R Plan to increase the number of shares of Common Stock reserved for issuance thereunder. For Against Abstain Broker Non-Votes 46,645,607 14,304,810 100,245 26,083,760

View on SEC.gov

1639 shareholder votes filed in the last 30 days. Browse all shareholder votes →

FATE THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001193125-26-271055

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.